603 related articles for article (PubMed ID: 16638032)
1. Guidelines following hydatidiform mole: a reappraisal.
Kerkmeijer L; Wielsma S; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):112-8. PubMed ID: 16638032
[TBL] [Abstract][Full Text] [Related]
2. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
3. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
4. Persistence of gestational trophoblastic disease for longer than 1 year following evacuation of hydatidiform mole.
Elmer DB; Granai CO; Ball HG; Curry SL
Obstet Gynecol; 1993 May; 81(5 ( Pt 2)):888-90. PubMed ID: 7682320
[TBL] [Abstract][Full Text] [Related]
5. Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy.
Wolfberg AJ; Feltmate C; Goldstein DP; Berkowitz RS; Lieberman E
Obstet Gynecol; 2004 Sep; 104(3):551-4. PubMed ID: 15339768
[TBL] [Abstract][Full Text] [Related]
6. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
7. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
8. Measurement of CA-125 in trophoblastic disease.
Kohorn EI
Gynecol Oncol; 2000 Jul; 78(1):39-42. PubMed ID: 10873407
[TBL] [Abstract][Full Text] [Related]
9. Low risk of relapse after achieving undetectable HCG levels in women with partial molar pregnancy.
Wolfberg AJ; Growdon WB; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
Obstet Gynecol; 2006 Aug; 108(2):393-6. PubMed ID: 16880311
[TBL] [Abstract][Full Text] [Related]
10. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy.
Wolfberg AJ; Berkowitz RS; Goldstein DP; Feltmate C; Lieberman E
Obstet Gynecol; 2005 Sep; 106(3):548-52. PubMed ID: 16135585
[TBL] [Abstract][Full Text] [Related]
11. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
Coyle C; Short D; Jackson L; Sebire NJ; Kaur B; Harvey R; Savage PM; Seckl MJ
Gynecol Oncol; 2018 Feb; 148(2):254-257. PubMed ID: 29229282
[TBL] [Abstract][Full Text] [Related]
12. Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies.
Growdon WB; Wolfberg AJ; Feltmate CM; Goldstein DP; Genest DR; Chinchilla ME; Berkowitz RS; Lieberman ES
J Reprod Med; 2006 Nov; 51(11):871-4. PubMed ID: 17165432
[TBL] [Abstract][Full Text] [Related]
13. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
14. Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.
Braga A; Maestá I; Matos M; Elias KM; Rizzo J; Viggiano MG
Gynecol Oncol; 2015 Nov; 139(2):283-7. PubMed ID: 26383828
[TBL] [Abstract][Full Text] [Related]
15. Serum human chorionic gonadotropin regression pattern in persistent trophoblastic disease during chemotherapy.
Lertkhachonsuk R; Limpongsanurak S
J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S352-9. PubMed ID: 11529357
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of women with recurrent molar pregnancies.
Lorigan PC; Sharma S; Bright N; Coleman RE; Hancock BW
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):288-92. PubMed ID: 10985882
[TBL] [Abstract][Full Text] [Related]
17. The impact of uterine re-curettage, pre-evacuation and week-one level of hCG on the number of chemotherapy courses in treatment of post molar GTN.
Hemida RA; Toson E; Van Doorn HC
J Exp Ther Oncol; 2011; 9(3):217-20. PubMed ID: 22070053
[TBL] [Abstract][Full Text] [Related]
18. Late spontaneous resolution of persistent molar pregnancy.
Taylor F; Short D; Harvey R; Winter MC; Tidy J; Hancock BW; Savage PM; Sarwar N; Seckl MJ; Coleman RE
BJOG; 2016 Jun; 123(7):1175-81. PubMed ID: 26774079
[TBL] [Abstract][Full Text] [Related]
19. Human chorionic gonadotropin follow-up in patients with molar pregnancy: a time for reevaluation.
Feltmate CM; Batorfi J; Fulop V; Goldstein DP; Doszpod J; Berkowitz RS
Obstet Gynecol; 2003 Apr; 101(4):732-6. PubMed ID: 12681878
[TBL] [Abstract][Full Text] [Related]
20. Predictors of persistent disease in women with complete hydatidiform mole.
Ayhan A; Tuncer ZS; Halilzade H; Küçükali T
J Reprod Med; 1996 Aug; 41(8):591-4. PubMed ID: 8866387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
